JP6449849B2 - 転移のインヒビター - Google Patents

転移のインヒビター Download PDF

Info

Publication number
JP6449849B2
JP6449849B2 JP2016506681A JP2016506681A JP6449849B2 JP 6449849 B2 JP6449849 B2 JP 6449849B2 JP 2016506681 A JP2016506681 A JP 2016506681A JP 2016506681 A JP2016506681 A JP 2016506681A JP 6449849 B2 JP6449849 B2 JP 6449849B2
Authority
JP
Japan
Prior art keywords
seq
peptide
cancer
mans
marcks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016506681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516756A (ja
JP2016516756A5 (enExample
Inventor
パリク，インドゥー
アドラー，ケネス・ビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of JP2016516756A publication Critical patent/JP2016516756A/ja
Publication of JP2016516756A5 publication Critical patent/JP2016516756A5/ja
Application granted granted Critical
Publication of JP6449849B2 publication Critical patent/JP6449849B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
JP2016506681A 2013-04-05 2014-04-07 転移のインヒビター Expired - Fee Related JP6449849B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
US61/808,966 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (3)

Publication Number Publication Date
JP2016516756A JP2016516756A (ja) 2016-06-09
JP2016516756A5 JP2016516756A5 (enExample) 2017-05-25
JP6449849B2 true JP6449849B2 (ja) 2019-01-09

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506681A Expired - Fee Related JP6449849B2 (ja) 2013-04-05 2014-04-07 転移のインヒビター

Country Status (19)

Country Link
US (4) US9408886B2 (enExample)
EP (1) EP2981279B1 (enExample)
JP (1) JP6449849B2 (enExample)
KR (1) KR102191695B1 (enExample)
CN (1) CN105517562B (enExample)
AU (1) AU2014247979B2 (enExample)
BR (1) BR112015025398A2 (enExample)
CA (1) CA2908832C (enExample)
DK (1) DK2981279T3 (enExample)
ES (1) ES2714863T3 (enExample)
HU (1) HUE043971T2 (enExample)
IL (1) IL241937B (enExample)
MX (1) MX363077B (enExample)
PL (1) PL2981279T3 (enExample)
PT (1) PT2981279T (enExample)
RU (1) RU2681213C2 (enExample)
SG (2) SG10201708125PA (enExample)
WO (1) WO2014165853A1 (enExample)
ZA (1) ZA201508010B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517562B (zh) * 2013-04-05 2018-12-28 拜欧马可医药公司 转移抑制剂
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂
EP4475866A4 (en) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptides and their methods of use in the treatment of eye disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
WO2003000027A2 (en) 2001-06-26 2003-01-03 North Carolina State University Blocking peptide for inflammatory cell secretion
JP2005523879A (ja) * 2001-10-05 2005-08-11 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Ｓｉｒｓ／ｓｅｐｓｉｓを治療及び予防するための組成物及び方法
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
WO2006078899A2 (en) 2005-01-20 2006-07-27 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors based on the structure of mans and methods of use
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
SG10201500418QA (en) * 2006-07-26 2015-03-30 Biomarck Pharmaceuticals Ltd Methods for attenuating release of inflammatory mediators and peptides useful therein
EP2069477A4 (en) * 2006-10-06 2010-12-08 Celtaxsys Inc Chemorepulsion of cells
JP2010508512A (ja) 2006-10-27 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 転移性結腸直腸癌のアッセイ
WO2009062128A2 (en) * 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP3351641A1 (en) * 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
CN105517562B (zh) * 2013-04-05 2018-12-28 拜欧马可医药公司 转移抑制剂

Also Published As

Publication number Publication date
IL241937B (en) 2019-03-31
PT2981279T (pt) 2019-03-14
WO2014165853A1 (en) 2014-10-09
EP2981279A1 (en) 2016-02-10
CA2908832C (en) 2023-01-24
RU2015146997A (ru) 2017-05-15
ZA201508010B (en) 2017-01-25
RU2681213C2 (ru) 2019-03-05
US9408886B2 (en) 2016-08-09
JP2016516756A (ja) 2016-06-09
NZ712955A (en) 2021-03-26
SG10201708125PA (en) 2017-11-29
DK2981279T3 (en) 2019-03-25
KR102191695B1 (ko) 2020-12-16
US10683328B2 (en) 2020-06-16
US20190119320A1 (en) 2019-04-25
EP2981279B1 (en) 2018-12-19
HUE043971T2 (hu) 2019-09-30
CA2908832A1 (en) 2014-10-09
US20210130403A1 (en) 2021-05-06
CN105517562A (zh) 2016-04-20
AU2014247979B2 (en) 2018-06-28
EP2981279A4 (en) 2016-11-09
MX363077B (es) 2019-03-07
MX2015014036A (es) 2016-02-25
HK1221159A1 (en) 2017-05-26
US20170121369A1 (en) 2017-05-04
BR112015025398A2 (pt) 2017-10-10
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
RU2015146997A3 (enExample) 2018-03-13
US10011636B2 (en) 2018-07-03
CN105517562B (zh) 2018-12-28
KR20150140736A (ko) 2015-12-16
SG11201508249WA (en) 2015-11-27
PL2981279T3 (pl) 2019-09-30
ES2714863T3 (es) 2019-05-30
AU2014247979A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
RU2756253C2 (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
WO2021098679A1 (zh) Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
KR102599712B1 (ko) C/EBP 알파 saRNA 조성물 및 사용 방법
US20110177155A1 (en) Methods of delivery of agents to leukocytes and endothelial cells
US11466054B2 (en) Inhibitors of metastasis
Ames et al. Identification of an endogenously generated cryptic collagen epitope (XL313) that may selectively regulate angiogenesis by an integrin yes-associated protein (YAP) mechano-transduction pathway
CN106659758A (zh) 用于免疫调节的组合物和方法
AU2016270710A1 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
TWI609692B (zh) 新穎ｓｔｉｐ１多肽及其用途
TW202031271A (zh) 用於惡性腫瘤之rna干擾輸送配方及方法
ES2843724T3 (es) Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral
US12201671B2 (en) Polypeptides for treatment of cancer
ES2338400B1 (es) Conjunto de moleculas antiangiogenicas y su uso.
HK1221159B (en) Mareks inhibitor peptides for inhibiting metastasis
US20190290728A1 (en) Methods related to breaking t cell exhaustion
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
US10413564B2 (en) Compositions and methods for combating drug-resistant cancers
WO2026069235A1 (en) Treatments for inflammation
Friesel et al. Jacquelyn, J. Ames, Liangru Contois, Jennifer M. Caron, Eric Tweedie, Xuehui Yang, Robert
NZ712955B2 (en) Inhibitors of metastasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181206

R150 Certificate of patent or registration of utility model

Ref document number: 6449849

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees